VISTAGEN THERAPEUTICS INC (VTGN)       0.1709  +0.01 (+8.3%)

0.1709  +0.01 (+8.3%)

US92840H2022 - Common Stock - After market: 0.17 0 (-0.53%)


Fundamental Rating

Taking everything into account, VTGN scores 3 out of 10 in our fundamental rating. VTGN was compared to 643 industry peers in the Biotechnology industry. The financial health of VTGN is medium. Also its profitability is quite bad. While showing a medium growth rate, VTGN is valued expensive at the moment.




Profitability

Profitability Rating


VTGN has negative profitability rations, so we won't be analyzing them here.
VTGN has a Return On Assets of -63.99%. This is below the industry average of -39.49%.

VTGN has a Profit Margin of -4307.19%. This is below the industry average of -433.79%. 83% of the industry peers outperform VTGN.
The Piotroski-F score of VTGN is 3.00. This is a low score and indicates issues in the health and profitability of VTGN.
VS Industry

ROA (-63.99%) VS Industry: 28% outperformed.

-1,226.49
115.38

Profit Margin (-4307.19%) VS Industry: 17% outperformed.

-436,406.25
5,207.39

Valuation

Valuation Rating


With a price book ratio of 0.55, VTGN is valued rather cheaply.
When comparing the price book ratio of VTGN to the average industry price book ratio of 1.95, VTGN is valued rather cheaply. VTGN is also cheaper than 87% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of VTGN to the average industry ratio of 0.78, VTGN is valued in line with its industry peers.

The Price/Earnings Ratio is negative for VTGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTGN. No positive earnings are expected for the next year.
VS Industry

Price/Book (0.55) VS Industry: 87% outperformed.

649.31
0.07

Enterprise Value/ EBITDA (0.76) VS Industry: 51% outperformed.

4,910.81
0.00

Growth

Growth Rating


The Earnings Per Share has grown by an impressive 35.90% over the past year.
VTGN is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 160.19% yearly.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

The Earnings Per Share is expected to grow by 9.92% on average over the next 5 years.
VTGN shows a small growth in Revenue. In the last year, the Revenue has grown by 2.50%.
The Revenue has been decreasing by -2.37% on average over the past 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 35.9% -16.28% -36.5% 0.23% 9.92%
Revenue-2.37% N/A 2.5% 6.26% 173.48% 163.67% 160.19%

Health

Health Rating


VTGN has a Current Ratio of 12.32. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
VTGN is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.90.
VTGN has a Quick Ratio of 12.32. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
VTGN is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.89.

Compared to an average industry Debt to Equity Ratio of 0.00, VTGN is more dependent on financing than its industry peers.
Based on the Altman-Z score of -4.13, we must say that VTGN is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of VTGN to the average industry Altman-Z score of 0.65, VTGN is less financially healthy than its industry peers.
VTGN has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of VTGN.
VS Industry

Debt/Equity (0) VS Industry: 39% outperformed.

20.91
-18.60

Quick Ratio (12.32) VS Industry: 71% outperformed.

0.04
141.63

Current Ratio (12.32) VS Industry: 71% outperformed.

0.15
141.63

Altman-Z (-4.13) VS Industry: 26% outperformed.

-257.46
1,422.64

Dividend

Dividend Rating


VTGN does not give a dividend.

VTGN Daily chart

VISTAGEN THERAPEUTICS INC0.1709

NASDAQ:VTGN (8/10/2022, 7:00:02 PM)+0.01 (+8.3%)

After market: 0.17 0 (-0.53%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 06-23 2022-06-23/amc Earnings (Next) 08-10 2022-08-10
Ins Owners 0.18% Inst Owners 65.19%
Market Cap 35.31M Analysts 88
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 31.85 P/B 0.55
EV/EBITDA 0.76
Profitability
ROA -63.99% ROE N/A
PM -4307.19 Asset Turnover 0.01
Growth
EPS 1Y 35.9% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 55%
EPS Next Y -16.28% EPS Next 2Y -36.5%
EPS Next 3Y 0.23% EPS Next 5Y 9.92%
Revenue growth 1Y 2.5% Revenue growth 3Y N/A
Revenue growth 5Y -2.37% Revenue growth Q2Q -91.2%
Revenue Next Year 6.26% Revenue Next 2Y 173.48%
Revenue Next 3Y 163.67% Revenue Next 5Y 160.19%
Health
Current Ratio 12.32 Quick Ratio 12.32
Altman-Z -4.13 F-Score 3
Debt/Equity N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA